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a97556 Effecte of CS1 ?eptida in a Porcine CoronaryModei of Restenosis
E. Shampaert, P.R.A.Caramori, S. Moloasi, P.H.Seidelin, S. Fort, M. Eliess,
Al. Gotlieb, A.G. Adalman, M. Rabinovitch. Toronto,Canada
The ECM glyeoprotein fibrona.tin is upregulated in rabbit, porcine and hu-
man reatenotic leeions. In addition to regulation of SMC migration, increased
fibroneetin has been associated with transendothelial trafficking of lympho-
cyte. Connecting eegment 1 (CS1) is the active recognition domain of
fibroneetin, binding to integrin receptors al@4. Our previous studies in a
rabbit allogenic heart transplant model showed that CS1 peptide downregu-
Iatea fibroneetin, prevents transendothelial migration of T cells and reduces
neointimal formation. The effects of CSI peptide was evaluated in a porcine
model of rsstenosis. Twenty domestic pigs subjected to oversized IAD coro-
nary angioplasly were randomized to receive CSI peptide (10 mglkg SC)or
acrambled peptides daily untii sacrifice 28 days later.
Reau/ts: Immunohiatology was carried out on sections stained with anti-
bodies to CS1 fibronectin and tenacin (another ECM protein recently impli-
cated in SMC migration)..
CS1oaciide Placebo D
CS1Fibronectin 5+/1++ 1+/5++or+++ 0.04
Tenacin 5+14++or+++ 1+/11++or+++ 0.046
Morphometry revealed no difference in neointimal (0.98 & 0.49 ve. 0.80
l0.62 mmz, p= 0.49), Iuminal (3.20* 1.34 vs. 3.12* 1.31 mm2,p= 0.90)
or vessel areas (5.34 & 1.90 vs. 5.20 4=1.02 mmz) between the groups.
Neointimal cell density waa aiso unaffected by CS1 peptide (4538 * 1380
vs. 4585 * 1386 cells/mm2, p = 0.94).
Conclusion: Despite effective downregulation of fibronectin and tenacin,
CS1 peptkfe did not inhibit naointima formation or improve vaacular remod-
eling in thia porcine model of restenosis.
D97557 Locai Deiivery of Tissue Factor Pathway inhibitor(TFPi) to Reduce Neointimai Proliferation in the
Porcine Coronary Baiioon injury Modei
S.R. Steinhubf, G. Belli, C.-J. Wu, J. Yom, J. Furst, G.R. Gellupi,
A.V. Kaplan, E.J. Topol, A.M. Lincoff. The Cleveland Clinic Foundation,
Cleveland, OH, USA
TFPI ie a novel antithrombotic agent that inhibits TF:Vlla and Factor Xa,
and hae been shown in animal modele to limit neointimal hyperplasia with
prolonged (24-72 hour) infuaions. To evaluate the impact of several deiive!y
strategies of TFPI on neointimal proliferation, 32 animals were randomly
assigned to 1 of 4 treatment groups: 1) Bolus TFPI (2 mg/kg over 20 rein)
followed by local delivety of 2.5 mg TFPI, 2) Bolus heparin (300 IU/kg) then
Iocsl delivety of 1000 IU heparin, 3) Bolus heparin (300 IUikg) then local
delivev of 2.5 mg TFPI, 4) 24 hr TFPI infusion (1.5 m~kg over 10 min then
25 @@rein). over-expansion balloon injuw (~ 30%) was performed to the
LAD and RCA, with local delivety using the lnfusaSleeve delivety syetem.
Animals were sacrificed 28 days later.
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Conclusion: of the strategies tested in this porcinecoronay vascular
injury model, the best inhibition of neointimal hyperplasia was obtained with
locally delivered TFPI after a brief (20 rein) infusion.
a97570 Abciximab (ReoPro, chimeric7E3 Fab)Cross-specificity with c@3 integrin Receptors: A
Potentiai Mechanism for the Prevention of
Restenosis
M.T. Nakada, R.E. Jordan, D.M. Knight. Cenkwori /nc. Ma/vein, PA, USA
Abciximab binds to GPllb/llia and reduces the incidence of adverse events
after coronary angioplasty ae demonstrated by the EPIC, EPILOG and CAP-
TURE trials. In addition to its effect on acute thrombotic complications, likely
due to ite ability to block GPllb/llla-mediated platelet aggregation, abciximab
aleo haa a longer term effect, reducing the incidence of ischemic compli-
cations at six months after angioplasty. The mechanism of this long-term
therapeutic effect may be due to cross specificity with another integrin, avp3,
which is present on vascular endothelial celis (ECS)and emooth muscle cella
(SMCS), but this binding has not been well characterized. We found that
abciximab binds to a@3 on cultured human ECe with an affinity (& = 0.37
~g/ml) comparable to that seen with GPllb/llla (F& = 0.26 wglml) and with
similar affinity to a variety of primary cell cultures including coronary artety
EGs,coronary artery and pulmonary artery SMCS,skeletal muscle cells, and
lung fibrobiasts. The binding of abciximab to avp3 is functionally blocking, as
abeiximab inhibits: 1) spreading of ECS on vitroneotin or fibrinogen coated
glass slides and 2) adhesion of avp~-expressing M21 melanoma cells to vit-
ronaetincoated plates (ICW = 0.34 #g/ml). Because @?3 plays an important
role in SMC and EC migration and proliferation eeen with restenosis, these
data are consistent with the hypothesis that blocking csvfJswith abeiximab
explains the prolonged efficacy observed in clinical trials.
1975-71 I The ROieofMediaiSmOoth MuscieCeiisinAtteriai
Repair - Re-Appraisai of an Oid Paradigm
A. Fard, Y. Shi, J.E. O’Brien, W.S. Chung, J.D. Mannion, A. Zalewski.
Thomas Jefferson Universi~ Phi/a., PA, USA
Mediaismcdh muscie(SM) cells are believed toplayacentral role invescular
repair. Recent etudias, however, demonatreted the activation of adventitial
fibroblaste and their contribution to naointimal formation after atterial injury.
The goal of this study was to m-evaluate the role of medial SM celle in
eorona~ repair.
Resu/te; Balloon injury or stent implantation produced @COMpletOmedial
disruption (lMD, no adventitial exposure to the lumen) or QOMpletemedial
~isruption (CMD, adventitial exposure tothelumen) in porcine ooronaryarter-
~e. At 3 days, medial SM cells were largely quiescent and their proliferation
was similar in IMD and CMD (1.6 * 0.9Y0vs 1.7 * 1.2%, NS). After baiioon
injury and IMD (n = 13), a low adventitial proliferation (4 & 1%) and the
abeence of myofibroblasts at 7 days were followed by the development of a
emall neointima at 30 days (0.23 * 0.11 mm). In contrast, balloon-induced
CMD (n= 23) raeultedina high adventitial proliferation at3days (37 *4%, p
c 0.001), myofibroblast formation (a-SM actin ~sitive) at 7 days foliowed by
a marked neointima at 30 days (0.88 * 0.30 mm, p < 0.02). Likewise, after
stent implantation, neointimal formation was dependent on adventitial injury
(iMD: n = 19,0.21 * 0.07mmvsCMD:n=33,0.77• 0.23 mm, p < 0.001).
Conclusions: 1.Medial SM cells showed a low proliferative activity after
coronary injury; 2. Absence of adventitial activation and limited neointimal
formation in the presence of preserved media suggests its protective role; 3.
Adventitial fibroblasta, rather than medial SM cells, are essential for arterial
remodeling.
975-72 Length-Dependencyof Phoephorothioate
Oiigodeoxynucieotides on the Non-Sequence
Specific inhibitory Effects of In VitroVascuiar
Smooth Muecie Ceii Proliferation and Migration
W. Wang, H.J. Chen, S. Yszdani, M. Campbell, A. Schwartz, C.A. Stein,
L.R.E. Rabbani. Division of Cardiology Columbia Univeraify New Yorfr,NY
USA
Phosphorothioate oligodeoxynucleotides (PSoligos) manifest both antisense
and Gquartet aptemeric inhibitory effects on vascular smooth muscle cell
(SMC) proliferation and migration. We have shown that S-dC26, a 28-mer
phoephorothioate cytidine homopolymer which lacks any guanosines, in-
hibits in vitro human aortic SMC proliferation and migration and neointima
formation in the ret carotid injury model. In order to determine whether the
length of PS oligos affects their non-G-quatiet, non-sequence specific ef-
feete on SMC proliferation, we examined the effects of S-dC28, S-dC16 and
S-dC12 on in vitro SMC proliferation. S-dC18 at mncentrations of 2 YM (p
< 0.04), 10 PM (p < 0.009) and 20 MM(p < 0.006) (n = 4) inhibited human
vascular SMC proliferation measured by a Coulter Counter, although it had
only half the potency as the same doses of S-dC28. Furthermore, S-dC14 at
the same doses as S-dCIS did not significantly inhibit SMC proliferation. We
next examined the effects of S-dC2S, S-dC18 and S-dC12 on in vitro SMC
migration determined in a modified micro-Boyden chamber. At a corrcentra-
tion of 20 PM, S-dC28 inhibited PDGF-induced SMC migration by 53% (p
< 0.0001) while S-dC16 inhibited by 40% (p c 0.002) (n = 5). S-dC12 did
not significantly inhibit PDGF-induced SMC migration. Taken together, these
data suggest that the potent non-G-quartet, non-sequence specific inhibito~
effects of S-dC compounds on in vitro SMC proliferation and migration are
length-dependent.
